血浆脂质与非酒精性脂肪性肝病及肝酶之间因果关系的孟德尔随机化分析

doi:10.13481/j.1671-587X.20260123

Abstract

Abstract:

Objective To investigate the potential causal associations of specific plasma lipids with nonalcoholic fatty liver disease （NAFLD） and liver enzymes， and elucidate the potential impact of specific plasma lipid on liver health. Methods Two-sample Mendelian randomization （MR） analyses were conducted to investigate potential causal relationships between 179 plasma lipids and both NAFLD and 4 liver enzymes： alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， gamma-glutamyl transferase （GGT）， and alkaline phosphatase （ALP）. The inverse-variance weighted method served as the primary analysis approach， supplemented by MR-Egger， weighted median， weighted mode， and simple mode. Sensitivity analyses including MR-Egger intercept test and MR-PRESSO Global test were conducted to ensure the reliability of the results. Multivariable MR analysis was conducted to adjust for the potential effect of body mass index （BMI） on the association between plasma lipids and NAFLD. Results The analyses revealed that phosphatidylcholine （18：0/20：5）［odd ratio（OR）=0.988， 95% confidence interval（CI）（0.977， 0.999）， P=0.028］ exhibited a protective effect on NAFLD， while phosphatidylinositol （16：0/18：2）［OR=1.016， 95%CI（1.000， 1.032）， P=0.046］ and phosphatidylinositol （18：0/18：2）［OR=1.012， 95%CI （1.002， 1.022）， P=0.021］ increased NAFLD risk. After adjustment for BMI， the association between phosphatidylinositol （18：0/18：2）［OR=1.019， 95%CI （1.007， 1.035）， P=0.008］ and NAFLD remained significant. Elevated levels of phosphatidylcholine （16：0/20：5）［β=0.026， 95%CI（0.015， 0.036）， P=9.93×10^-7］， phosphatidylcholine （O-16：0/22：5）［β=0.057， 95%CI（0.035， 0.078）， P=1.79×10^-7］， triacylglycerol （56：7）［β=0.057， 95%CI （0.035，0.079）， P=2.53×10^-7］ and triacylglycerol （56：8）［β=0.067， 95%CI （0.047，0.087）， P=1.19×10^-10］ were significantly associated with increased ALT levels. Triacylglycerol （53：2）［β=0.160， 95% CI （0.123， 0.197）， P=1.55×10^-17］ showed a significant positive causal association with AST levels. Conclusion Specific plasma lipids were causally associated with NAFLD risk and liver enzyme levels， with some associations independent of BMI.

Key words: Plasma lipidome, Liver enzymes, Nonalcoholic fatty liver disease, Mendelian randomization, Causal association

CLC Number:

R575.5

Zhifei LIU,Yaru BI,Chenglin SUN,Suyan TIAN. Mendelian randomization analysis on causal association between plasma lipids with nonalcoholic fatty liver disease and liver enzymes[J].Journal of Jilin University(Medicine Edition), 2026, 52(1): 219-227.

Figures/Tables 6

Tab.1

Tab.2

Fig. 1

Tab.3

Tab.4

Fig. 2

References 28

[1]	BRUNT E M， WONG V WS， NOBILI V， et al. Nonalcoholic fatty liver disease［J］. Nat Rev Dis Primer， 2015， 1（1）： 15080.
[2]	PARLATI L， RÉGNIER M， GUILLOU H， et al. New targets for NAFLD［J］. JHEP Rep， 2021， 3（6）： 100346.
[3]	POWELL E E， WONG V WS， RINELLA M. Non-alcoholic fatty liver disease［J］. The Lancet， 2021， 397（10290）： 2212-2224.
[4]	CALZADILLA BERTOT L， ADAMS L. The natural course of non-alcoholic fatty liver disease［J］. Int J Mol Sci， 2016， 17（5）： 774.
[5]	SHEARER G C， BORKOWSKI K， PUUMALA S L， et al. Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids［J］. Prostaglandins Leukot Essent Fatty Acids， 2018， 128： 1-10.
[6]	AMOR A J， PINYOL M， SOLÀ E， et al. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities： A focus on atherogenic dyslipidemia［J］. J Clin Lipidol， 2017， 11（2）： 551-561.e7.
[7]	DEPRINCE A， HAAS J T， STAELS B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease［J］. Mol Metab， 2020， 42： 101092.
[8]	DU T， SUN X， YUAN G， et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease［J］. Metabolism， 2016， 65（9）： 1391-1398.
[9]	CHEN Z， TIAN R， SHE Z， et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease［J］. Free Radic Biol Med， 2020， 152： 116-141.
[10]	GINANNI CORRADINI S， ZERBINATI C， MALDARELLI F， et al. Plasma fatty acid lipidome is associated with cirrhosis prognosis and graft damage in liver transplantation［J］. Am J Clin Nutr， 2014， 100（2）： 600-608.
[11]	VELENOSI T J， BENYAKOV G， PODSZUN M C， et al. Postprandial plasma lipidomics reveal specific alteration of hepatic-derived diacylglycerols in non-alcoholic fatty liver disease［J］. Gastroenterology， 2022， 162（7）： 1990-2003.
[12]	CHAMBERS J C， ZHANG W， SEHMI J， et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma［J］. Nat Genet， 2011， 43（11）： 1131-1138.
[13]	LARSSON S C， BUTTERWORTH A S， BURGESS S. Mendelian randomization for cardiovascular diseases： principles and applications［J］. Eur Heart J， 2023， 44（47）： 4913-4924.
[14]	OTTENSMANN L， TABASSUM R， RUOTSALAINEN S E， et al. Genome-wide association analysis of plasma lipidome identifies 495 genetic associations［J］. Nat Commun， 2023， 14（1）： 6934.
[15]	SUN Z， PAN X， TIAN A， et al. Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals［J］. JHEP Rep， 2023， 5（7）： 100744.
[16]	BARTON A R， SHERMAN M A， MUKAMEL R E， et al. Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses［J］. Nat Genet， 2021， 53（8）： 1260-1269.
[17]	YENGO L， SIDORENKO J， KEMPER K E， et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700 000 individuals of European ancestry［J］. Hum Mol Genet， 2018， 27（20）： 3641-3649.
[18]	CAO Y， AI M， LIU C. The impact of lipidome on breast cancer： a Mendelian randomization study［J］. Lipids Health Dis， 2024， 23（1）： 109.
[19]	TIWARI-HECKLER S， GAN-SCHREIER H， STREMMEL W， et al. Circulating phospholipid patterns in NAFLD patients associated with a combination of metabolic risk factors［J］. Nutrients， 2018， 10（5）： 649.
[20]	SONG J， COSTA K ADA， FISCHER L M， et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease （NAFLD）［J］. FASEB J， 2005， 19（10）： 1266-1271.
[21]	LI Z， VANCE D E. Phosphatidylcholine and choline homeostasis［J］. J. Lipid Res.， 2008， 49（6）： 1187-1194.
[22]	ZHANG J， ZANG X， LV J， et al. Changes in lipidomics， metabolomics， and the gut microbiota in CDAA-induced NAFLD mice after polyene phosphatidylcholine treatment［J］. Int J Mol Sci， 2023， 24（2）： 1502.
[23]	YU Y， CAI J， SHE Z， et al. Insights into the epidemiology， pathogenesis， and therapeutics of nonalcoholic fatty liver diseases［J］. Adv Sci， 2019， 6（4）： 1801585.
[24]	KUDO Y， TANAKA Y， TATEISHI K， et al. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway［J］. J Hepatol， 2011， 55（6）： 1400-1408.
[25]	SHIROUCHI B， NAGAO K， INOUE N， et al. Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in zucker （fa/fa） rats［J］. J. Agric Food Chem， 2008， 56（7）： 2375-2379.
[26]	BROWNING J D， HORTON J D. Molecular mediators of hepatic steatosis and liver injury［J］. J Clin Invest， 2004， 114（2）： 147-152.
[27]	TIROSH O， ILAN E， ANAVI S， et al. Nutritional lipid-induced oxidative stress leads to mitochondrial dysfunction followed by necrotic death in FaO hepatocytes［J］. Nutrition， 2009， 25（2）： 200-208.
[28]	MAEV I V， SAMSONOV A A， PALGOVA L K， et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities： real-life observational study from Russia［J］. BMJ Open Gastroenterol， 2020， 7（1）： e000368.

Phenotype	Year	Data resources	PubMed ID	GWAS Catalog accession	Sample size	Ancestry
Plasma lipids	2023	GeneRISK	37907536	GCST90277238-GCST90277416	7 174	European
NAFLD	2023	SUN Z, et al	37235137	GCST90275041	32 941	European
ALT	2021	BARTON A R, et al	34226706	GCST90025979	437 724	European
AST	2021	BARTON A R, et al	34226706	GCST90025980	436 275	European
GGT	2021	BARTON A R, et al	34226706	GCST90025966	437 651	European
ALP	2021	BARTON A R, et al	34226706	GCST90025947	437 896	European
BMI	2018	GIANT	30124842	GCST006900	681 275	European

Exposure	nSNP	OR (95%CI)	P	MR-Egger intercept P	MR-PRESSO Global P	Cochran’s Q test P
Phosphatidylcholine (18：0/20：5)	14	0.988(0.977,0.999)	0.028	0.131	0.895	0.921
Phosphatidylcholine (O-16：0/16：1)	11	0.982(0.966,0.999)	0.035	0.071	0.451	0.454
Phosphatidylcholine (O-16：0/18：2)	9	1.020(1.001,1.040)	0.041	0.306	0.887	0.937
Phosphatidylcholine (O-16：0/22：5)	8	0.979(0.961,0.997)	0.023	0.265	0.752	0.757
Phosphatidylcholine (O-16：1/20：4)	11	0.989(0.978,1.000)	0.044	0.769	0.985	0.995
Phosphatidylcholine (O-18：1/20：4)	9	0.981(0.966,0.996)	0.014	0.395	0.645	0.559
Phosphatidylcholine (O-18：2/16：0)	12	1.021(1.004,1.038)	0.013	0.630	0.354	0.299
Phosphatidylinositol (16：0/18：2)	19	1.016(1.000,1.032)	0.046	0.183	0.061	0.065
Phosphatidylinositol (18：0/18：2)	22	1.012(1.002,1.022)	0.021	0.686	0.078	0.098
Sphingomyelin (d40：2)	9	1.020(1.001,1.040)	0.041	0.306	0.887	0.937

Exposure	Without adjustment OR (95%CI)	Adjust for BMI OR (95%CI)	MVMR P
Phosphatidylcholine (18：0/20：5)	0.988(0.977,0.999)	1.000(0.962,1.014)	0.843
Phosphatidylinositol (16：0/18：2)	1.016(1.000,1.032)	0.993(0.944,1.031)	0.147
Phosphatidylinositol (18：0/18：2)	1.012(1.002,1.022)	1.019(1.007,1.035)	0.008

Exposure	Outcome	nSNP	β（95%CI）	P	MR-Egger intercept P	MR-PRESSO Global P	Cochran's Q test P
Sterol ester (27：1/20：5)	ALT	5	0.054(0.030,0.077)	6.96E-06	0.227	0.492	0.379
Phosphatidylcholine (16：0/20：5)	ALT	6	0.026(0.015,0.036)	9.93E-07	0.378	0.444	0.491
Phosphatidylcholine (O-16：0/22：5)	ALT	4	0.057(0.035,0.078)	1.79E-07	0.380	0.396	0.193
Triacylglycerol (56：7)	ALT	7	0.057(0.035,0.079)	2.53E-07	0.657	0.144	0.060
Triacylglycerol (56：8)	ALT	7	0.067(0.047,0.087)	1.19E-10	0.764	0.314	0.124
Triacylglycerol (53：2)	AST	4	0.160(0.123,0.197)	1.55E-17	0.988	0.261	0.339

Mendelian randomization analysis on causal association between plasma lipids with nonalcoholic fatty liver disease and liver enzymes

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 28

Related Articles 7

Metrics

Comments

Recommended 0

[1]	Xianlei ZHOU,Zimo YAN,Liwen GUO,Xuemei ZHANG. Mendelian randomization analysis based on causal association of sterol esters with occurrence of intrahepatic ductal, biliary, and gallbladder malignancy [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1084-1093.
[2]	Xianwei JIANG,Minghang WANG,Huiru LI,Xiaosheng DONG,Yuanyuan LIU. Mendelian randomization and GEO database identification analysis based on potential therapeutic targets for chronic obstructive pulmonary disease [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1072-1083.
[3]	Xingyun SUN,Fuyao LI,Kexin LI,Jing SHI. Causal relationship between tinnitus and risk of Alzheimer’s disease analyzed by Mendelian randomization [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1052-1060.
[4]	Huaxia MU,Weixiao BU,Shuting DING,Mengyao GAO,Weiqiang SU,Zhen ZHANG,Qifu BO,Feng LIU,Fuyan SHI,Qinghua WANG,Yujia KONG,Suzhen WANG. Two sample Mendelian randomization study on causal relationship between insulin-like growth factor-1 and colorectal cancer [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 479-485.
[5]	Zhifei LIU,Yaru BI,Chenglin SUN,Suyan TIAN. Mendelian randomization analysis based on causal relationship between gut microbiota and gestational diabetes mellitus [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1381-1389.
[6]	Huaqing LIU,Qingkai CHEN,Yongxin CHEN,Runhao QIU,Xupeng DING,Fengjing SONG,Yan WANG,Baolin WANG,Hong CAO. Mendelian randomization study based on relationship between lifestyle and occurrence and development of hepatobiliary malignancies [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 778-785.
[7]	LIU Min,KONG Xiang-xin,YANG Ping,CHEN Yu-bin,LI Xiao-kun,WANG Hui-yan. Effect of fibroblast growth factor-21 \|on lipid metabolism of nonalcoholic fatty liver disease cell model induced \|in vitro [J]. J4, 2012, 38(3): 477-481.